Abeona Therapeutics (NASDAQ:ABEO) Cut to Sell at StockNews.com

by · The Cerbat Gem

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday.

Several other brokerages also recently issued reports on ABEO. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, October 29th.

Check Out Our Latest Stock Analysis on ABEO

Abeona Therapeutics Trading Down 0.7 %

NASDAQ ABEO traded down $0.04 on Thursday, hitting $5.96. 176,742 shares of the stock were exchanged, compared to its average volume of 266,048. The company’s 50-day moving average price is $5.97 and its two-hundred day moving average price is $5.64. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The company has a market capitalization of $259.09 million, a price-to-earnings ratio of -2.22 and a beta of 1.46.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in Abeona Therapeutics in the 3rd quarter worth about $84,000. Charles Schwab Investment Management Inc. acquired a new position in Abeona Therapeutics in the third quarter worth approximately $151,000. XTX Topco Ltd acquired a new position in Abeona Therapeutics in the third quarter worth approximately $160,000. JPMorgan Chase & Co. raised its position in Abeona Therapeutics by 74.2% during the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after acquiring an additional 28,606 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after acquiring an additional 2,434 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also